A Feasibility Trial Evaluating the Addition of Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms NICOLAS
- 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 08 May 2015 New trial record